HYDROMORPHON
B-All
Merck Sharp & Dohme LLCSmall moleculePhase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the B-All cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cd22 car-transduced t cells National Cancer Institute (NCI) | Phase 2 | BB |
Ketorolac Tromethamine Merck Sharp & Dohme LLC | Phase 2/3 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Merck Sharp & Dohme LLC | Phase 2/3 | B |
FENTANYL Merck Sharp & Dohme LLC | Phase 2/3 | B |
Acalabrutinib Acerta Pharma BV | Phase 1/2 | CCC |
View all 9 →
Same molecule, other indications
HYDROMORPHON is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →